Realizing the Potential of PCSK9 Inhibition A Novel Oral Macrocyclic Peptide on the Horizon

被引：0
|
作者：
Chapman, M. John [1 ,2 ,3 ,5 ]
Packard, Chris J. [4 ]
机构：
[1] Sorbonne Univ, Fac Med, Paris, France
[2] Pitie Salpetriere Univ Hosp, Cardiovasc Dis Prevent Unit, Paris, France
[3] Natl Inst Hlth & Med Res, INSERM, Paris, France
[4] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow City, Scotland
[5] Pitie Salpetriere Univ Hosp, Cardiovasc Dis Prevent Unit, 83, Blvd lHop, F-75651 Paris 13, France
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2023年 / 81卷 / 16期
关键词：
atherosclerotic cardiovascular disease; LDL cholesterol; lipoprotein(a); oral macrocyclic PCSK9 inhibitor; PCSK9; remnant lipoproteins; triglyceride-rich lipoproteins; CARDIOVASCULAR-DISEASE;
D O I：
10.1016/j.jacc.2023.03.384
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1565 / 1568
页数：4
相关论文
共 50 条
  • [1] New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide
    Landmesser, Ulf
    Makhmudova, Umidakhon
    CIRCULATION, 2023, 148 (02) : 159 - 161
  • [2] An oral antisense oligonucleotide for PCSK9 inhibition
    Gennemark, Peter
    Walter, Katrin
    Clemmensen, Niclas
    Rekic, Dinko
    Nilsson, Catarina A. M.
    Knochel, Jane
    Holtta, Mikko
    Wernevik, Linda
    Rosengren, Birgitta
    Kakol-Palm, Dorota
    Wang, Yanfeng
    Yu, Rosie Z.
    Geary, Richard S.
    Riney, Stan J.
    Monia, Brett P.
    Isaksson, Rikard
    Jansson-Lofmark, Rasmus
    Rocha, Cristina S. J.
    Linden, Daniel
    Hurt-Camejo, Eva
    Crooke, Rosanne
    Tillman, Lloyd
    Ryden-Bergsten, Tina
    Carlsson, Bjorn
    Andersson, Ulf
    Elebring, Marie
    Tivesten, Anna
    Davies, Nigel
    SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (593)
  • [3] Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression
    Shapiro, Michael D.
    Tavori, Hagai
    Oleaga, Carlota
    Miles, Joshua
    Fazio, Sergio
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
  • [4] An Oral Antisense Oligonucleotide for PCSK9 Inhibition in Humans
    Gennemark, Peter
    Walter, Katrin
    Clemmensen, Niclas
    Rekic, Dinko
    Nilsson, Catarina
    Knoechel, Jane
    Holtta, Mikko
    Wang, Yanfeng
    Yu, Rosie
    Riney, Stanley
    Monia, Brett P.
    Andersson, Ulf
    Jansson-Lofmark, Rasmus
    Rocha, Cristina S.
    Linden, Daniel
    Ryden-Bergsten, Kristina
    Hurt-Camejo, Eva
    Crooke, Rosanne M.
    Tillman, Lloyd
    Carlsson, Bjorn
    Elebring, Marie
    Tivesten, Anna
    Davies, Nigel
    CIRCULATION, 2020, 142
  • [5] The immunogenic potential of PCSK9 peptide vaccine in mice
    Ataei, S.
    Momtazi-Borojeni, A. A.
    Jaafari, M. R.
    Banach, M.
    Sahebkar, A. A.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2354 - 2354
  • [6] The Immunogenic Potential of PCSK9 Peptide Vaccine in Mice
    Ataei, Sarina
    Momtazi-Borojeni, Amir Abbas
    Ganjali, Shiva
    Banach, Maciej
    Sahebkar, Amirhossein
    CURRENT MEDICINAL CHEMISTRY, 2023, 30 (26) : 3024 - 3031
  • [7] Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia
    Stawowy, Philipp
    Just, Isabell A.
    Kaschina, Elena
    CORONARY ARTERY DISEASE, 2014, 25 (04) : 353 - 359
  • [8] Inhibition of PCSK9 as a Novel Strategy for the Treatment of Hypercholesterolemia
    Lopez, Dayami
    DRUG NEWS & PERSPECTIVES, 2008, 21 (06) : 323 - 330
  • [9] Oral PCSK9 Inhibitors
    Anandita Agarwala
    Ramsha Asim
    Christie M. Ballantyne
    Current Atherosclerosis Reports, 2024, 26 : 147 - 152
  • [10] Oral PCSK9 Inhibitors
    Agarwala, Anandita
    Asim, Ramsha
    Ballantyne, Christie M.
    CURRENT ATHEROSCLEROSIS REPORTS, 2024, 26 (05) : 147 - 152
12345